Valuation: Mirum Pharmaceuticals, Inc.

Market Cap 6.1B 5.28B 4.99B 4.52B 8.49B 585B 8.55B 59.6B 22.93B 297B 22.9B 22.39B 946B P/E 2026 *
-6.21x
P/E 2027 * -117x
Enterprise Value 6.28B 5.44B 5.14B 4.66B 8.74B 602B 8.8B 61.36B 23.61B 305B 23.58B 23.06B 974B EV / Sales 2026 *
9.01x
EV / Sales 2027 * 7.56x
Free-Float
98.34%
Yield 2026 *
-
Yield 2027 * -
1 day-2.95%
1 week-5.66%
Current month-4.23%
1 month-6.70%
3 months-7.03%
6 months+3.57%
Current year+18.88%
1 week 93.57
Extreme 93.57
103.28
1 month 93.57
Extreme 93.57
104.66
Current year 73.82
Extreme 73.82
130
1 year 63.23
Extreme 63.232
130
3 years 23.14
Extreme 23.14
130
5 years 12.82
Extreme 12.82
130
10 years 6.51
Extreme 6.5126
130
Manager TitleAgeSince
Chief Executive Officer 47 2019-03-20
Director of Finance/CFO 66 2023-09-10
President 48 2024-01-15
Director TitleAgeSince
Chairman 73 2019-03-20
Director/Board Member 55 2018-11-06
Director/Board Member 47 2018-10-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/2/26 Sell

Controller/Auditor

-658 0.0010%
9/1/26 Exercice

Founder

90,000 0.1386%
8/18/26 Exercice

Controller/Auditor

120,000 0.1968%
Change 5-day change 1-year change 3-year change Capi.($)
-2.95%-5.66%+26.57%+185.84% 6.1B
-0.19%+1.09%+51.85%+97.36% 1,013B
+0.33%-0.71%+50.62%+65.50% 644B
+0.49%+5.73%+20.88%+72.92% 465B
+0.55%+2.88%+38.48%+37.98% 352B
+0.53%+1.82%+16.57%+23.39% 264B
+0.36%+2.02%+6.15%+10.75% 253B
-1.53%-4.46%+36.90%+44.08% 203B
+0.34%-5.51%-22.30%-58.60% 188B
-0.08%-0.23%+30.00%+93.34% 181B
Average -0.03%-1.54%+25.57%+57.26% 356.98B
Weighted average by Cap. +0.64%+0.00%+34.50%+59.64%

Financials

2026 *2027 *
Net sales 697M 603M 571M 517M 969M 66.82B 977M 6.81B 2.62B 33.88B 2.62B 2.56B 108B 816M 707M 668M 605M 1.14B 78.27B 1.14B 7.98B 3.07B 39.69B 3.07B 3B 127B
Net income -933M -808M -764M -692M -1.3B -89.5B -1.31B -9.12B -3.51B -45.38B -3.5B -3.43B -145B -32.99M -28.58M -27.02M -24.47M -45.92M -3.16B -46.26M -322M -124M -1.6B -124M -121M -5.12B
Net Debt 181M 157M 148M 134M 252M 17.36B 254M 1.77B 680M 8.8B 680M 665M 28.07B 74.95M 64.92M 61.39M 55.58M 104M 7.19B 105M 733M 282M 3.65B 282M 275M 11.63B
Logo Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States, Canada and Japan. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
Employees
433
Date Price Change Volume
26-09-15 US$93.90 -2.95% 948,708
26-09-14 US$96.75 -1.50% 488,542
26-09-11 US$98.22 -2.38% 441,100
26-09-10 US$100.61 +2.35% 587,036
26-09-09 US$98.30 -1.24% 521,761
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
93.90USD
Average target price
138.21USD
Spread / Average Target
+47.18%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MIRM Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!